U.S. patent application number 10/721498 was filed with the patent office on 2004-06-17 for low molecular weight heparin assay, system and reagent therefor.
This patent application is currently assigned to CARDIOVASCULAR DIAGNOSTICS INC.. Invention is credited to Mize, Patrick D..
Application Number | 20040115753 10/721498 |
Document ID | / |
Family ID | 21712538 |
Filed Date | 2004-06-17 |
United States Patent
Application |
20040115753 |
Kind Code |
A1 |
Mize, Patrick D. |
June 17, 2004 |
Low molecular weight heparin assay, system and reagent therefor
Abstract
A method, kit, system and reagent for measuring low molecular
weight heparin in a whole blood sample is provided which involves
the use of a Factor Xa activator, such as Russell's Viper Venom, as
the coagulation assay initiator.
Inventors: |
Mize, Patrick D.; (Durham,
NC) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
CARDIOVASCULAR DIAGNOSTICS
INC.
Morrisville
NC
|
Family ID: |
21712538 |
Appl. No.: |
10/721498 |
Filed: |
November 26, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10721498 |
Nov 26, 2003 |
|
|
|
10004791 |
Dec 7, 2001 |
|
|
|
6680177 |
|
|
|
|
Current U.S.
Class: |
435/13 |
Current CPC
Class: |
G01N 33/86 20130101;
Y10S 435/975 20130101; C12Q 1/56 20130101 |
Class at
Publication: |
435/013 |
International
Class: |
C12Q 001/56 |
Claims
1. A method for measuring low molecular weight heparin
concentration on a whole blood sample, comprising: (i) combining a
first, whole blood, component of the assay with a second component
of the assay to form a resulting mixture, wherein said second
component comprises a dry coagulation assay reagent arranged in a
substantially flattened configuration and containing magnetic
particles distributed substantially homogeneously therethrough and
comprising a factor Xa activator, and wherein said resulting
mixture is subjected to (ia) an oscillating magnetic field or (ib)
a moving permanent magnetic field or (ic) a combination of an
oscillating magnetic field and a stationary permanent magnetic
field or (id) a rotating magnetic field, whereby said combining of
said first component with said second component substantially
simultaneously initiates movement of said magnetic particles and a
coagulation assay measurement; and (ii) monitoring movement induced
in said magnetic particles by (ia) or (ib) or (ic) or (id) to
obtain said coagulation assay measurement, wherein said coagulation
assay measurement correlates to a concentration of low molecular
weight heparin in the whole blood sample.
2. The method of claim 1, wherein said whole blood sample is a
citrated whole blood sample.
3. The method of claim 1, wherein said magnetic particles are
induced to move by applying an oscillating magnetic field
thereto.
4. The method of claim 1, wherein said magnetic particles are
induced to move by applying a moving permanent magnetic field
thereto.
5. The method of claim 1, wherein said method is carried out in an
element for performing said method, said method comprising adding
said first, whole blood, component to said element, wherein said
element comprises a channel structure defining a sample well and a
reaction volume in fluid communication with each other, said
reaction volume containing said second component, said channel
structure having a geometry causing said first, whole blood,
component placed in said sample well to be drawn into and filling
said reaction volume via capillary action, wherein, after said
reaction volume is filled, said first, whole blood, component
remains stationary therein.
6. The method of claim 5, wherein said element further comprises a
means for channeling light from an outside source to said reaction
volume.
7. The method of claim 6, further comprising using a means for
detecting light scattered or absorbed or reflected from said
reaction volume.
8. The method of claim 7, wherein said element is disposed in
sufficiently close proximity to a permanent magnet and to an
electromagnet such that said permanent magnet and said
electromagnet provide said combination of an oscillating magnetic
field and a stationary permanent magnetic field.
9. The method of claim 8, wherein said element is situated between
said permanent magnet and said electromagnet.
10. The method of claim 1, wherein said magnetic particles are
induced to move by application of a rotating magnetic field.
11. The method of claim 1, wherein said Factor Xa activator is
Russell's Viper Venom.
12. The method of claim 1, wherein said low molecular weight
heparin is enoxaparin.
13. A method for measuring low molecular weight heparin
concentration on a whole blood sample, comprising: (i) adding a
whole blood sample to a sample well of an element comprising: a
channel structure defining the sample well and a reaction volume in
fluid communication with each other, wherein said reaction volume
is defined by an upper surface having attached thereto a
reflectance layer, comprising a semipermeable matrix wherein said
reaction volume contains a measured amount of at least one dry
coagulation assay reagent arranged in a substantially flattened
configuration and containing magnetic particles distributed
substantially homogeneously therethrough, wherein a specific volume
of said sample is drawn into said reaction volume by capillary
action and contacts, together with said semipermeable layer, said
reagent to thereby substantially simultaneously initiate a
coagulation assay measurement; and (ii) performing said coagulation
assay measurement by measurement the reflectance of said
semipermeable layer, wherein said dry coagulation assay reagent
comprises a Factor Xa activator.
14. A kit for measuring low molecular weight heparin concentration
on a whole blood sample, comprising, in one or more containers, a
permanent magnet, a timing means, and an element containing at
least one dry coagulation assay reagent arranged in a substantially
flattened format and containing magnetic particles distributed
substantially homogeneously therethrough, wherein said at least one
dry coagulation assay reagent comprises a Factor Xa activator.
15. The kit of claim 14, further comprising a transfer pipette.
16. The kit of claim 15, wherein said transfer pipette is made of
an essentially nonthrombogenic material, comprises a vented end, is
capable of being filled with a liquid sample by capillary action,
and is capable of expelling said liquid sample by means of pressure
after covering or sealing said vented end.
17. A system for measuring low molecular weight heparin
concentration on a whole blood sample, comprising: (i) an
instrument with a means for temperature control, a means for
producing an oscillating magnetic field or for moving a permanent
magnetic field, an illuminating means, and a photometric monitoring
means; and (ii) an element for performing said measuring, said
element comprising a channel structure defining a sample well and
reaction volume in fluid communication with each other, said
channel structure having a geometry causing a liquid sample placed
in said sample well to be drawn into and filling said reaction
volume via capillary action, said reaction volume comprising at
least one dry coagulation assay reagent arranged in a substantially
flattened configuration and containing magnetic particles
distributed substantially homogeneously therethrough, wherein said
at least one dry coagulation assay reagent comprises a Factor Xa
activator.
18. The system of claim 17, further comprising a transfer
pipette.
19. The system of claim 18, wherein said transfer pipette is made
of an essentially nonthrombogenic material, comprises a vented end,
is capable of being filled with a liquid sample by capillary
action, and is capable of expelling said liquid sample by means of
pressure after covering or sealing said vented end.
20. The system of claim 17, wherein said instrument further
comprises a heating means comprising a resistive heater strip and a
thermistor situated in close proximity to said element.
21. The system of claim 17, wherein said element is suitable for
performing a whole blood coagulation assay, said channel structure
having a geometry causing a blood sample placed in said sample well
to be drawn into and filling said reaction volume via capillary
action, wherein after said reaction volume is filled, said blood
sample remains stationary therein, and wherein said element further
comprises an optically or magnetically encodable information means,
or both, capable of providing at least one of calibration, quality
control, test parameter and patient information.
22. The system of claim 17, wherein said illuminating means
includes one or more light sources to illuminate said element and
wherein said photometric monitoring means comprises one or more
detectors for photometrically monitoring chromogenic or
chromomodulating species present in said reaction volume.
23. A system for measuring low molecular weight heparin
concentration in a whole blood sample, comprising: (i) a reaction
element comprising (1) a sample well for receiving a liquid sample
and (2) a reaction chamber containing a dry coagulation assay
reagent arranged in a substantially flattened configuration and in
which is embedded, substantially homogeneously therethrough,
magnetic particles; (ii) said sample well and said reaction chamber
being in fluid communication through a transport zone of geometry
such that a volume of liquid sample placed in said sample well and
corresponding to the volume of said reaction chamber is transported
from said sample well to said reaction chamber simultaneously;
(iii) means for optically monitoring said reaction chamber; (iv)
means for subjecting said reaction chamber to an oscillating
magnetic field; (v) whereby, when said sample is introduced into
said reaction chamber, said dry coagulation assay reagent is
solubilized and said magnetic particles are thereby freed to move
in an oscillating pattern induced by said oscillating magnetic
field, thus providing a measurement of the kinetics of said
coagulation assay corresponding to changes in the degree of said
magnetic particles movement relative to said oscillating magnetic
field, wherein said dry coagulation assay reagent comprises a
Factor Xa activator.
24. The system of claim 23, further comprising a means for
controlling the moment transport of said liquid sample from said
sample well to said reaction chamber is initiated.
25. The system of claim 23, further comprising a plurality of
reaction chambers in fluid communication with said sample well, and
means for transporting a whole blood or plasma sample from one of
said plurality of reaction chambers to another of said plurality of
reaction chambers.
26. A method for measuring low molecular weight heparin
concentration in a whole blood sample, comprising: (i) subjecting
to an oscillating magnetic field a reaction element bearing (1) a
sample well for receiving a whole blood sample and (2) a reaction
chamber containing a dry coagulation assay reagent arranged in a
substantially flattened format and in which is embedded,
substantially homogeneously therethrough, magnetic particles, said
sample well and reaction chamber being in fluid communication
through a transport zone of geometry such that a volume of sample
placed in said sample well and corresponding to the volume of said
reaction chamber is transported from said sample well to said
reaction chamber simultaneously; (ii) adding the whole blood sample
susceptible to coagulation to said sample well whereby at least a
part of said sample is introduced simultaneously to said reaction
chamber, said reagent is solubilized and said particles are freed
to move in an oscillating pattern induced by said oscillating
magnetic field; and (iii) optically monitoring said reaction
chamber to measure kinetics for the coagulation assay corresponding
to changes in the degree of said particle movement relative to said
magnetic field, wherein said dry coagulation assay reagent
comprises a Factor Xa activator.
Description
BACKGROUND OF THE INVENTION
[0001] 1. Field of Invention
[0002] The present invention relates to a dry chemistry format
assay for measuring the low molecular weight heparin content of a
whole blood sample, and a system and reagent for performing such an
assay.
[0003] 2. Discussion of the Background
[0004] Low molecular weight heparins (LMWHs) are a heterogeneous
group of antithrombotic drugs produced from unfractionated heparin
(UFH) using diverse chemical and enzymatic processes. LMWHs, like
UFH, exhibit an anticoagulant effect by complexing with
antithrombin (AT) to inactivate several of the coagulation enzymes
preventing fibrin formation. Of these, Factor Xa and thrombin (IIa)
are the most responsive to inhibition. LMWHs, introduced as
antithrombotic drugs in the mid-1980s, are now established as the
drug of choice for surgical thromboprophylaxis and are increasingly
replacing UFH in the acute treatment of venous thromboembolic
disorders. The low molecular weight heparin, enoxaparin,
increasingly is used in patients with unstable angina (UA) and
non-Q-wave myocardial infarction (NQMI) (J. Fareed et al, Past,
present and future considerations on low molecular weight heparin
differentiation: an epilogue. Semin Thromb Hemost, 25 Suppl 3:145-7
(1999), and J. Hirsh et al, Heparin and low-molecular-weight
heparin: mechanisms of action, pharmacokinetics, dosing,
monitoring, efficacy, and safety. Chest, Jan;119(1 Suppl):64S-94S
(2001)), who transition to percutaneous coronary intervention (PCI)
(Lovenox (enoxaparin sodium) injection package insert,
.COPYRGT.1998, rev. 01/2001). Although the activated partial
thromboplastin time (aPTT) and activated clotting time (ACT) are
the most common methods used to monitor UFH, they are relatively
insensitive to LMWHs, such as enoxaparin. While chromogenic anti-Xa
assays are commonly used to monitor the concentration of LMWHs,
such assays provide an indirect measure of drug concentration and
results are not routinely available in a cardiac catheterization
laboratory setting.
[0005] The LMWHs have mean molecular weights between 4000 to 6000
daltons, and they have less ability to inactivate thrombin compared
to UFH. Each LMWH is a specific mixture often demonstrating a
unique anti-Xa/anti-IIa ratio and signature anticoagulant profile.
The result is an anti-Xa/anti-IIa ratio of approximately 3 to 14:1
(depending on the brand of LMWH, dosage, and route of
administration) compared to the 1:1 ratio observed with
UFH.sup.(Lovenox P.I.). The LMWH, enoxaparin, has a mean molecular
weight of approximately 4,500 daltons and, given at a dose of 1.5
mg/kg subcutaneously (SC), is characterized by a higher ratio of
anti-Factor Xa to anti-Factor IIa activity (mean.+-.SD, 14.0+3.1)
(based on areas under anti-Factor activity versus time curves)
compared to the ratios observed for heparin (mean.+-.SD,
1.22.+-.0.13).sup.(Lovenox P.I.). This is an important distinction
because the ability to prolong the APTT and ACT is proportional to
anti-IIa activity. Chromogenic anti-Xa assays provide estimates of
enoxaparin concentration only in dilute, supplemented plasma and
are not suitable for point-of-care (POC) testing.
[0006] More recently, clinical trials have confirmed the safety and
efficacy of the LMWH, enoxaparin sodium (Lovenox.RTM.,
Clexane.RTM.), in the management of acute coronary syndromes (ACS)
(J. Fareed et al., Thromosis and Hemostasis, Supplement 3, Vol. 25,
3-4 (1999)).
[0007] Blood clotting reactions, in general, are employed as
clinical assays to measure the time required for the formation of a
fibrin clot. Blood clotting assays are principally used for
screening, diagnosis, and for monitoring patients receiving
anticoagulant therapy. There are many types of coagulation assays.
These include prothrombin time (PT), partial thromboplastin time
(PTT), activated partial thromboplastin time (APTT), fibrinogen
assay, thrombin clotting time (TCT), activated clotting time (ACT),
etc.
[0008] Before performing conventional clotting tests, a blood
sample is collected in a tube or syringe containing anticoagulant
(citrate). The blood sample is centrifuged, and the plasma
separated (e.g., by decantation) from the red blood cells. A
measured quantity (usually 0.1 ml) of plasma is pipetted into the
reaction vessel or cuvette. A measured amount of reagent is then
added manually via pipette or automatically by means of other
volumetric delivery systems capable of metering a known, preset
quantity of reagent. Alternatively, the sample can be added to the
reagent directly.
[0009] Typically, 0.2 ml of reagent is employed. The addition of
the reagent initiates the reaction. Many existing blood clotting
assays suffer from at least one of the following disadvantages:
difficulty in performance, requirement of highly trained personnel,
inaccuracy in measurement, reagent instability, large consumption
of reagent, etc.
[0010] One solution to this problem was addressed in Oberhardt,
U.S. Pat. No. 5,110,727, in which a dry reagent based reaction
slide is provided for performing coagulation assays quickly,
accurately and simply. Such tests are marketed by Pharmanetics,
Inc.
[0011] The capacity of blood to clot, as well as to not clot, is
dependent on a large number of enzymatic factors and cofactors. The
ability of central clinical laboratories to reliably and
conveniently assay for LMWH in whole blood or plasma samples can be
critical in monitoring individuals in LMWH therapy. The blood
coagulation system is dominated by sequential proteolytic
activation reactions of inactive precursors, called zymogens.
Forward clotting reactions are controlled by simultaneous
activation of anticoagulant zymogens that serve to limit the extent
of clot formation and initiate the fibrinolytic system to resolve
the clot.
[0012] There is thus a strongly felt need for a simple, facile and
accurate method for the performance of blood clotting assays, e.g.,
in medical applications. Such a method should be based on a minimum
number of manipulations of either a sample or reagent. Ideally such
a method should be easily utilized by persons without extensive
clinical laboratory training and should require no sample or
reagent-containing solution preparation. It should not suffer the
problems associated with reagent instability and be very accurate.
It should permit effective mixing of sample and reagent. It should
require only a very small amount of sample. And it should be able
to perform automatic treatments of the sample, e.g., it should not
require centrifugation of the blood sample or any other off line
cell separation process. Available clotting parameter assays
likewise suffer salient disadvantages.
[0013] Since the tests currently used for LMWHs are chromogenic
assays requiring isolation of derived plasma from whole blood
samples and significant processing time for performing the assay,
an assay is needed that can quantitatively measure LMWHs quickly
and easily, using whole blood and be performed at the bedside, in
order to provide rapid determinations of LMWH therapeutic
levels.
[0014] Additionally, conventional chromogenic assays measure actual
levels of LMWH in the plasma sample, but do not reflect the actual
clotting dynamics of the patient's blood. Since the clotting
dynamics can depend or be confounded by a variety of factors, a
test is needed that will correlate the clotting time with the
amount of LMWH in the sample, and will also detect other possible
problems in the clotting dynamics that are independent of the
LMWH.
[0015] Clotting parameter assays are referred to herein as function
and structure-based assays in the broad realm of coagulation
diagnostics which do not utilize clot formation or clot lysis
processes to generate end points. Most of these assays utilize
chromogenic synthetic substrates to quantify molecular markers or
specific factors or components associated with coagulation. These
are typically functional reaction based assays as opposed to most
immunoassays which could detect the same molecules but utilize
structure recognition and may therefore still identify inhibited
components or defective components, neither of which may be
functional.
SUMMARY OF THE INVENTION
[0016] Accordingly, one object of the present invention is to
provide an improved coagulation assay for LMWHs, particularly
enoxaparin.
[0017] A further object of the present invention is to provide such
an assay that can be performed using whole blood.
[0018] A further object of the present invention is to provide such
an assay that is based on a dry chemistry format.
[0019] A further object of the present invention is to provide
reagents for coagulation assays for measurement of LMWHs.
[0020] A further object of the present invention is to provide a
coagulation based assay in dry chemistry format that relates
clotting time to LMWH levels in a whole blood sample, while
remaining sensitive to factors that can affect clotting time of the
sample.
[0021] These and other objects of the present invention have been
satisfied by the discovery of assays, reagents, methods and kits
for measuring low molecular weight heparin concentration in a whole
blood sample using a coagulation cascade reaction and monitoring
coagulation times or kinetics, wherein the coagulation reagent is a
dry format reagent comprising magnetic particles and a Factor Xa
activator, such as Russell's Viper Venom.
BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Many attendant features of this invention will become
readily appreciated as the same becomes better understood by
reference to the following detailed description when considered in
connection with the accompanying drawings:
[0023] FIG. 1 provides a graphical depiction of the relevant
portion of the coagulation cascade in blood.
[0024] FIG. 2 provides a graphical representation of the in vitro
clotting time response of citrated whole blood at different levels
of the preferred LMWH enoxaparin.
[0025] FIG. 3 provides a graphical representation of in vitro
clotting time response of citrated whole blood at varying levels of
four other LMWHs.
[0026] FIG. 4 shows the response of the preferred ENOX test and the
corresponding derived plasma anti-Xa values as a function of time
from enoxaparin administration.
[0027] FIG. 5 shows the relationship between the ENOX test clot
times for CWB and STACHROM.RTM. LMWH anti-Xa IU/ml values (from
derived plasma) in a small clinical trial.
[0028] FIG. 6 shows the results of a study on depletion of various
factors in blood samples on the ENOX test clot times.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] The present invention relates to a method for measuring low
molecular weight heparin concentration on a whole blood sample,
comprising:
[0030] (i) combining a first, whole blood, component of the assay
with a second component of the assay, wherein the second component
comprises a dry coagulation assay reagent arranged in a
substantially flattened configuration and containing magnetic
particles distributed substantially homogeneously therethrough and
comprising a factor Xa activator, and wherein the resulting mixture
is subjected to (ia) an oscillating magnetic field or (ib) a moving
permanent magnetic field or (ic) a combination of an oscillating
magnetic field and a stationary permanent magnetic field or (id) a
rotating magnetic field, whereby the combining of the first
component with the second component substantially simultaneously
initiates movement of the magnetic particles and a coagulation
assay measurement; and
[0031] (ii) monitoring movement induced in the magnetic particles
by (ia) or (ib) or (ic) or
[0032] (id) to obtain the coagulation assay measurement, wherein
the coagulation assay measurement correlates to a concentration of
low molecular weight heparin in the whole blood sample.
[0033] In the method of the present invention, the method is
carried out in an element for performing the method, wherein the
element comprises a channel structure defining a sample well and a
reaction volume in fluid communication with each other, the
reaction volume preferably containing the second component. The
channel structure preferably has a geometry causing the first,
whole blood, component placed in the sample well to be drawn into
and fill the reaction volume via capillary action, wherein, after
the reaction volume is filled, the first, whole blood, component
(now combined with the second component and forming a resulting
reaction mixture) remains stationary therein.
[0034] The element further preferably a means for channeling light
from an outside source to the reaction volume, such as those
described in the Pharmanetics patents. The method of the present
invention further comprises using a means for detecting light
scattered or absorbed or reflected from the reaction volume to
monitor the reaction. Suitable means for detecting light are
described in the Pharmanetics patents. Preferably, the reaction
element is disposed in sufficiently close proximity to a permanent
magnet and to an electromagnet such that the permanent magnet and
the electromagnet provide a combination of an oscillating magnetic
field and a stationary permanent magnetic field. More preferably,
the element is situated between the permanent magnet and the
electromagnet.
[0035] The present invention further relates to a method for
measuring low molecular weight heparin concentration on a whole
blood sample, comprising:
[0036] (i) adding a whole blood sample to a sample well of an
element comprising:
[0037] a channel structure defining the sample well and a reaction
volume in fluid communication with each other, wherein the reaction
volume is defined by an upper surface having attached thereto a
reflectance layer, comprising a semipermeable matrix wherein the
reaction volume contains a measured amount of at least one dry
coagulation assay reagent arranged in a substantially flattened
configuration and containing magnetic particles distributed
substantially homogeneously therethrough, wherein a specific volume
of the sample is drawn into the reaction volume by capillary action
and contacts, together with the semipermeable layer, the reagent to
thereby substantially simultaneously initiate a coagulation assay
measurement; and
[0038] (ii) performing the coagulation assay measurement by
measurement the reflectance of the semipermeable layer, wherein the
dry coagulation assay reagent comprises a Factor Xa activator.
[0039] The present invention further relates to a kit for measuring
low molecular weight heparin concentration on a whole blood sample,
comprising, in one or more containers, a permanent magnet, a timing
means, and an element containing at least one dry coagulation assay
reagent arranged in a substantially flattened format and containing
magnetic particles distributed substantially homogeneously
therethrough, wherein the at least one dry coagulation assay
reagent comprises a Factor Xa activator. Additionally, the present
invention relates to a system for measuring low molecular weight
heparin concentration on a whole blood sample, comprising:
[0040] (i) an instrument with a means for temperature control, a
means for producing an oscillating magnetic field or for moving a
permanent magnetic field, an illuminating means, and a photometric
monitoring means; and
[0041] (ii) an element for performing the measuring, the element
comprising a channel structure defining a sample well and reaction
volume in fluid communication with each other, the channel
structure having a geometry causing a liquid sample placed in the
sample well to be drawn into and filling the reaction volume via
capillary action, the reaction volume comprising at least one dry
coagulation assay reagent arranged in a substantially flattened
configuration and containing magnetic particles distributed
substantially homogeneously therethrough, wherein the at least one
dry coagulation assay reagent comprises a Factor Xa activator.
[0042] The system of the present invention can further comprise a
transfer pipette, preferably made of an essentially nonthrombogenic
material, and comprising a vented end. The transfer pipette is
preferably capable of being filled with a liquid sample by
capillary action, and is capable of expelling the liquid sample by
means of pressure after covering or sealing the vented end. The
instrument of the system further can comprise a heating means
comprising a resistive heater strip and a thermistor situated in
close proximity to the element. In the system of the present
invention, the element is preferably suitable for performing a
whole blood coagulation assay, with the channel structure having a
geometry causing a blood sample placed in the sample well to be
drawn into and filling the reaction volume via capillary action,
wherein after the reaction volume is filled, the blood sample
remains stationary therein, and wherein the element further
comprises an optically or magnetically encodable information means,
or both, capable of providing at least one of calibration, quality
control, test parameter and patient information. The illuminating
means of the system preferably includes one or more light sources
to illuminate the element. The photometric monitoring means
preferably comprises one or more detectors for photometrically
monitoring chromogenic or chromomodulating species present in the
reaction volume. Suitable means for the physical devices of the
system of the present invention are described in the Pharmanetics
patents.
[0043] The present invention further preferably relates to a system
for measuring low molecular weight heparin concentration in a whole
blood sample, comprising:
[0044] (i) a reaction element comprising (1) a sample well for
receiving a liquid sample and (2) a reaction chamber containing a
dry coagulation assay reagent arranged in a substantially flattened
configuration and in which is embedded, substantially homogeneously
therethrough, magnetic particles;
[0045] (ii) the sample well and reaction chamber being in fluid
communication through a transport zone of geometry such that a
volume of liquid sample placed in the sample well and corresponding
to the volume of the reaction chamber is transported from the
sample well to the reaction chamber simultaneously;
[0046] (iii) means for optically monitoring the reaction
chamber;
[0047] (iv) means for subjecting the reaction chamber to an
oscillating magnetic field;
[0048] (v) whereby, when the sample is introduced into the reaction
chamber, the dry coagulation assay reagent is solubilized and the
magnetic particles are thereby freed to move in an oscillating
pattern induced by the oscillating magnetic field, thus providing a
measurement of the kinetics of the coagulation assay corresponding
to changes in the degree of the magnetic particles movement
relative to the oscillating magnetic field, wherein the dry
coagulation assay reagent comprises a Factor Xa activator.
[0049] The system preferably further comprises a means for
controlling the moment transport of the liquid sample from the
sample well to the reaction chamber is initiated. Suitable such
means are described in the Pharmanetics patents. The system of the
present invention can further comprise a plurality of reaction
chambers in fluid communication with the sample well, and means for
transporting a whole blood or plasma sample from one of the
plurality of reaction chambers to another of the plurality of
reaction chambers. In such an arrangement, it is possible to have
the patient sample be split among the plurality of reaction
chambers, with each reaction chamber having different coagulation
reagents present for monitoring different aspects of the patients
blood. Suitable such plural reaction chamber elements are likewise
described in the Pharmanetics patents.
[0050] The present invention further relates to a method for
measuring low molecular weight heparin concentration in a whole
blood sample, comprising:
[0051] (i) subjecting to an oscillating magnetic field a reaction
element bearing (1) a sample well for receiving a whole blood
sample and (2) a reaction chamber containing a dry coagulation
assay reagent arranged in a substantially flattened format and in
which is embedded, substantially homogeneously therethrough,
magnetic particles, the sample well and reaction chamber being in
fluid communication through a transport zone of geometry such that
a volume of sample placed in the sample well and corresponding to
the volume of the reaction chamber is transported from the sample
well to the reaction chamber simultaneously;
[0052] (ii) adding the whole blood sample susceptible to
coagulation to the sample well whereby at least a part of the
sample is introduced simultaneously to the reaction chamber, the
reagent is solubilized and the particles are freed to move in an
oscillating pattern induced by the oscillating magnetic field;
and
[0053] (iii) optically monitoring the reaction chamber to measure
kinetics for the coagulation assay corresponding to changes in the
degree of the particle movement relative to the magnetic field,
wherein the dry coagulation assay reagent comprises a Factor Xa
activator.
[0054] The present invention relates to an assay for a LMWH, in
particular for enoxaparin (ENOX), in a whole blood sample using a
dry chemistry format reagent. Preferable assay elements (such as
test cards) and their methods of preparation are described in U.S.
Pat. Nos. 4,849,340; 5,110,727; 5,350,676; 5,508,521; 5,601,991;
5,658,723; 5,670,329; 5,677,133; 6,165,795; and 6,197,494, the
entire contents of which are hereby incorporated by reference
(hereafter referred to as the "Pharmanetics patents"). However, the
assay can be performed using assay elements of other types, as
described below.
[0055] The present invention assay is designed to provide rapid
results of the anticoagulant effect provided by LMWH, preferably
enoxaparin sodium (Lovenox.RTM., Clexane.RTM.). It is a one-step
coagulation method performed on the Rapidpoint Coag analyzer,
available from Bayer Corp. or on the TAS analyzer, available from
Pharmanetics, Inc. The test utilizes citrated or non-citrated whole
blood. Like other test devices described in the Pharmanetics
patents, the LMWH test is a dry chemistry test card. All of the
components necessary to perform the test, with the exception of the
patient sample, are included within the reaction chamber of the
card.
[0056] In the assay of the present invention, factor X is rapidly
converted to factor Xa by the reagent containing a factor Xa
activator, such as Russells' viper venom (RVV-X), initiating the
clotting process, see FIG. 1. The assay element, preferably a test
card as described in the Pharmanetics patents, contains the Factor
Xa activator, but all clotting factors necessary for test function
(Factor X and V, prothrombin, fibrinogen, and antithrombin) are
supplied by the patient's sample. The assay measures the combined
anti-Xa and anti-IIa activity of the low molecular weight heparin
and is designed to measure clot times in citrated whole blood (CWB)
over a broad range of comparable spiked-CWB derived plasma
activities. Conventional tests for LMWH are only applicable up to
about a range of anti-Xa activities from 0.0 to 1.0 anti-Xa IU/ml.
However, the present assay provides the combined anti-Xa and
anti-IIa activity of the LMWH and measures clot times in CWB
comparable to a spiked-CWB derived plasma with an anti-Xa range of
0.0 to 3.0 anti-Xa IU/ml LMWH. The results generated by the present
assay are indicative of the overall anticoagulant effect produced
by the LMWH in whole blood.
[0057] The reagent comprises magnetic particles and a factor Xa
activator. Suitable factor Xa activators include various Xa
activating enzymes derived from snake venoms, including but not
limited to Russell's Viper Venom (RVV-X), Vipera aspis aspis,
Bothrops atrox, Saw-scaled viper Echis carinatus venom, and
Cerastes cerastes venom.
[0058] The LMWH assay reagent of the present invention may further
comprise one or more members selected from the group consisting of
buffers, lyophilization aids, non-ionic detergents and proteins.
Suitable buffers include, but are not limited to, HEPES, TRIS, and
PIPES in the pH range of from 6.0 to 8.0, more preferably from pH
6.0-7.0, most preferably from pH 6.3-6.8. Preferred lyophilization
aids include, but are not limited to, sucrose, lactose, mannitol
and trehalose, with trehalose being most preferred. Non-ionic
detergents are preferably one or more polysiloxanes combined with
one or more detergents selected from Pluronic.RTM. surfactants, and
PEO/PPO block copolymers. These components are preferably used in a
combination of 1-10wt % polysiloxane and 90-99 wt % of the
Pluronic.RTM. or PEO/PPO block copolymer, most preferably in a 1:99
ratio of polysiloxane: Pluronic.RTM. or PEO/PPO block copolymer.
The polysiloxanes used therein can be any polysiloxane type
detergent, preferably polydimethylsiloxane PDMS detergents. The
proteins useful in the present reagent preferably include, but are
not limited to bovine serum albumin (BSA) and ovalbumin, with BSA
being most preferred.
[0059] In the present assay, factor X is rapidly converted to
factor Xa by the factor Xa activator, initiating the clotting
process. The LMWH, preferably enoxaparin, from the patient's blood,
complexes with antithrombin, to inhibit factor Xa and lengthen the
clotting time in a dose-dependent manner. The reported clotting
time increases in a dose dependent manner to the LMWH concentration
present in the sample. The results generated by the test are
indicative of the anticoagulant effect produced by the LMWH in
whole blood.
[0060] Additionally, the results of the present assay can be used
to determine if a patient is responding normally to LMWH therapy.
For example, in certain patients, the blood is lacking in
antithrombin, an essential factor needed for the anticoagulant
effect of UFH or LMWH to work. When such a patient is monitored
using conventional chromogenic LMWH assays, the assay returns only
the level of LMWH, without reflecting the clotting dynamics of the
patient's coagulation system. However, with the test of the present
invention, one obtains a clotting time measurement that will
readily show the physician that the level of LMWH is having little
or no effect on the patient, since their clotting time will be
relatively unchanged upon addition of increasing levels of LMWH.
This will quickly tell the physician that there is another issue at
play in the patient's anticoagulation status, thereby saving
precious time in modifying the therapy. Using the conventional
chromogenic tests, such results would require two or more tests to
obtain and could easily be missed.
[0061] The test card of the present invention can be used to
monitor the effects of the low molecular weight heparin (LMWH),
preferably of Lovenox.RTM./Clexane.RTM. (enoxaparin, sodium), in
citrated or non-citrated whole blood.
[0062] The test provides information on patient's whole blood
response to LMWH, such as enoxaparin by measurement of the clotting
time using a factor Xa activated clotting method. To the present
inventors' knowledge, the present assay provides the first assay
for LMWH that can be accurately performed using whole blood.
[0063] In the present invention, the magnetic particles are induced
to move by being subjected to either (I) an oscillating magnetic
field or (2) a moving permanent magnetic field or (3) a combination
of an oscillating magnetic field and a stationary permanent
magnetic field, or (4) a rotating magnetic field. The movement of
the magnetic particles is then monitored in the performance of the
assay. The magnetic field of the present invention can be generated
using any of the magnetic field generating means described in the
Pharmanetics patents. The movement of the magnetic particles is
preferably detected and analyzed also as described in the
Pharmanetics patents.
[0064] The clotting assays of this invention are performed on a
reaction element. This reaction element can be any element which
will support the reagents used in the assay and permit monitoring
movement of the magnetic particles. Such reaction elements include
microtiter plates, their equivalents, substantially flat surfaces
or the reaction slide provided by the Pharmanetics patents.
[0065] The magnetic particles of the present invention assays are
present in an amount of 0.5, or lower, to 50 milligrams of magnetic
particles, preferably 1 to 10 milligrams, per milliliter of dry
reagent.
[0066] Examples of this invention are set forth below. However, it
is to be understood that these examples are given by way of
illustration only and are not to be construed as limiting the
invention either in spirit or in scope, as many modifications both
in doses and methods could be possible to those skilled in the
art.
EXAMPLES
[0067] Dose Response for Enoxaaparin embodiment of present assay An
in vitro dose-response relationship between mean ENOX CWB clotting
times for 10 individuals and the derived plasma enoxaparin
concentrations is shown in FIG. 2 and TABLE 1.
1TABLE 1 Combined In Vitro Response of Rapidpoint .RTM. Coag ENOX
Test to Enoxaparin in CWB from 10 Individual Donors Mean Anti-Xa*
0.0 0.38 0.82 1.92 3.0 Mean C.T. 122.8 203.1 256.8 320.7 380.7 SD
21.1 24.9 27.3 34.7 40.2 *Anti-Xa measured in derived plasma by
Stago StaChrom/MLA Electra 900C.
[0068] Whole blood from a normal adult was drawn into a Vacutainer
brand sample collection tube containing 0.105M (3.2%) sodium
citrate at the ratio of 9 parts blood to 1 part citrate. After
mixing the tube by gentle inversion, the citrated whole blood was
aliquoted into plastic tubes and supplemented with the low
molecular weight heparin (LMWH), Lovenox.RTM. (enoxaparin sodium)
to yield five whole blood enoxaparin solutions with nominal
concentrations ranging from about 0.0 to about 3.0 IU/ml
enoxaparin. Each sample was tested once on a dry-chemistry LMWH
test. The whole blood solutions were centrifuged within 5 minutes
to obtain platelet poor plasma. The platelet poor plasma was then
tested for enoxaparin concentration using the chromogenic
STACHROM.RTM. LMWH assay (catalog #00906; Parsippany, N.J.),
performed on an Electra 900C analyzer (Medical Laboratory
Automation, Inc., Pleasantville, N.Y.). The results were calibrated
to a preparation of enoxaparin (Aventis UN WSD3075). This procedure
was repeated for a total of ten normal adults. Individual results
and the average for all 10 individuals is shown in Table 2 and FIG.
2.
2TABLE 2 In Vitro Response of the Low Molecular Weight Heparin
(LMWH) Test to enoxaparin in Whole Blood R (correlation) Enoxaparin
concentration* 0.00 0.32 0.76 2.29 2.98 Donor 1 LMWH Test 142.7
222.1 253.0 312.3 444.8 0.951 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.37 0.78 1.94 2.75 Donor 2 LMWH Test 127.6
193.8 259.6 346.8 405.2 0.981 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.33 0.75 1.67 3.29 Donor 3 LMWH Test 147.7
259.1 314.8 396.0 420.1 0.872 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.35 0.75 1.67 2.32 Donor 4 LMWH Test 104.8
196.8 260.5 309.6 351.0 0.944 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.41 0.81 1.64 2.70 Donor 5 LMWH Test 139.0
214.8 270.1 316.6 422.8 0.983 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.37 0.80 1.82 3.16 Donor 6 LMWH Test 152.0
206.8 272.0 350.8 381.1 0.942 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.46 0.88 2.18 3.30 Donor 7 LMWH Test 101.2
192.0 238.2 290.8 337.2 0.938 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.44 0.93 2.23 3.32 Donor 8 LMWH Test 111.1
196.6 252.6 307.6 365.5 0.95 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.37 0.87 1.82 2.96 Donor 9 LMWH Test 101.2
177.8 236.1 297.8 348.9 0.958 Clotting Time (seconds) Enoxaparin
concentration* 0.00 0.41 0.82 1.97 3.04 Donor 10 rep1 101.0 171.3
210.8 278.2 330.5 0.972 Average Enoxaparin 0.00 0.38 0.82 1.92 2.98
Concentration Average LMWH Test 122.8 203.1 256.8 320.7 380.7 0.963
Clotting Time (seconds) STDEV 21.1 24.9 27.3 34.7 40.2
[0069] These results show an increasing clotting time to increasing
concentrations of enoxaparin and good correlation to the laboratory
reference test.
[0070] The mean correlation (r) of the 10 individual dose-response
relationship was 0.963.
[0071] 5
[0072] Preferred Enoxaparin embodiment A small clinical trial was
conducted at four centers with consenting patients primarily
receiving enoxaparin for treatment of acute coronary syndromes
and/or percutaneous coronary intervention (PCI) (n=35) and
secondarily those receiving enoxaparin for prevention of deep
venous thrombosis (DVT) during total knee/hip replacement
(TKHR)(n=8). Two to four samples were collected from TKHR patients
receiving subcutaneous (30 mg-BID SC) dosing with enoxaparin.
Samples were collected to reflect peak anti-Xa activity (3-5 hours
after dose) and at the nadir (just prior to dosing) to obtain
samples that span the entire range of anti-Xa activity. At least 3
samples were collected in patients undergoing PCI. PCI patients
received drug via intravenous (IV) bolus (0.75 mg/kg) at the start
of the procedure (D. J. Kereiakes et al., Combination enoxaparin
and abciximab therapy during percutaneous coronary intervention:
"NICE guys finish first". J Invasive Cardiol Feb;12 Suppl A:IA-5A,
(2000)). Samples were collected pre-drug administration (baseline),
peak (5-15 minutes after bolus), therapeutic range (45-60 minutes
after bolus), and then just prior to pulling the sheath (approx.
8-10 hours after bolus). Patients receiving UFH, direct thrombin
inhibitors, and vitamin K antagonists were not eligible for this
study. Batch anti-Xa determinations were performed using the
STACHROM.RTM. LMWH assay (Diagnostica Stago, Parsippany, N.J.) on
an Electra 900C analyzer (Medical Laboratory Automation, Inc.,
Pleasantville, N.Y.) which measures anti-Xa activity using the
amidolytic method. The results were calibrated to a standard
preparation of enoxaparin (L/N WSD3075 Aventis Pharmaceuticals,
Inc., Strasbourg 67917, France). Samples were collected at four
sites from 31 male and 12 female patients. Demographics, date of
birth, sex, age, height, weight, and total body surface area (TBSA)
of each patient are found in TABLE 3. The primary indication for
hospitalization at Site 3 was for knee and hip replacement surgery
while at the other sites the indication was for PCI. Treatment
information at the four contributing sites is summarized in Table
4. The inclusion of IV administered enoxaparin achieved anti-Xa
levels from 1-2 anti-Xa IU/ml in derived plasma. A total of 116
samples from 43 patients were included in this study.
3TABLE 3 Demographics of the Enoxaparin Test Clinical Trial Gender
Site Female Male Total Age (Yrs) Height (cm) Weight (kg) TBSA (m2)
1 4 16 20 Mean 67.4 173.2 83.4 2.00 Max 83 188.0 111.2 2.41 Min 48
150.0 53.0 1.49 2 3 4 7 Mean 65 166.1 88.5 2.02 Max 80 185.0 102.1
2.19 Min 54 129.5 77.7 1.69 3 2 6 8 Mean 60.5 164.1 70.2 1.78 Max
69 190.5 96.0 2.25 Min 37 152.4 50.0 1.48 4 3 5 8 Mean 63.3 169.3
73.8 1.85 Max 78 185.0 93.0 2.16 Min 51 157.0 42.2 1.36 All 12 31
43 Mean 64.9 169.6 80.0 1.93 Sites Max 83 190.5 111.2 2.41 Min 37
129.5 42.2 1.36
[0073]
4TABLE 4 Dosing Regimes from Sites and Primary Indication Sites
Treatment Primary Indication 1 0.75 mg/kg IV PCI/PTCA 2 0.75 mg/kg
IV PCI 3 30 mg qd SC Orthopedic Surgery 4 0.73 to 1.07 mg/kg IV
PCI
[0074] Clotting times (CT) from citrated whole blood CWB samples
ranged from 80 to 470 seconds as measured by the Rapidpoint.RTM.
ENOX test. Fifty-one samples (44%) had CT of 199 seconds or less,
36 samples (31%) had a CT of 200 to 300 seconds, and 29 samples
(25%) had a CT of greater than 300 seconds. The population
coefficient of variation (CV) for duplicate clot time measurements
was 8.8% in whole blood. These coefficients of variation are
acceptable. Corresponding derived-plasma enoxaparin concentrations
ranged from 0.0 to 1.8 anti-Xa IU/ml. Distribution of enoxaparin
concentrations observed in the plasma derived from these clinical
samples (n=116) was 41 samples (36%)<0.1 IU/ml, 49 samples (43%)
0.1 tc 1.0 IU/ml, and 26 samples (22%) 1.1 to 1.8 IU/ml as measured
by Stago Stachrom anti-Xa assay. The population coefficient of
variation for the STACHROM.RTM. (LMWH method using duplicate
anti-Xa IU/ml measurements was 9.4%. This relatively high CV may be
due to the additional error introduced by dilution of samples that
contain enoxaparin concentrations beyond the range of the
STACHROM.RTM. LMWH test (This range is 0.01 .about.1.0 anti-Xa
IU/ml).
[0075] The relationship between the ENOX test clot times for CWB
and STACHROM.RTM. LMWH anti-Xa IU/ml values (from derived plasma)
are shown in FIG. 5. Correlation between the ENOX test card clot
times and the STACHROM.RTM. LMWH results is shown with linear
regression and has a correlation coefficient (r) of 0.805. A
similar relationship between the ENOX test and the STACHROM.RTM.
LMWH was observed if the results of individual clot time
measurements were compared to the single STACHROM.RTM. LMWH anti-Xa
IU/ml measurement (r=0.777). Overall, the trial provided an
appropriate concentration range of enoxaparin containing samples
for evaluation of the ENOX test card, especially for PCI patients
in the range of 0.6 to 1.8 anti-Xa IU/ml of enoxaparin (J. P.
Collet et al, Percutaneous coronary intervention after subcutaneous
enoxaparin pretreatment in patients with unstable angina pectoris.
Circulation Feb 6;103(5):658-63 (2001)).
[0076] FIG. 4 shows the response of the ENOX test and the
corresponding derived plasma anti-Xa values as a function of time
from enoxaparin administration. The two sets of data mirror each
other with the peak in vivo enoxaparin concentration occurring
within 10 minutes of injection and ENOX test follows the
pharmacokinetics of enoxaparin.
[0077] INTERFERENCE STUDIES
[0078] A. Deficient plasma studies In vitro studies were performed
with normal pooled and affinity-depleted plasmas to determine the
factor sensitivities of the test. At the plasma equivalent of 1.0
anti-Xa IU/ml enoxaparin clotting time increased 20% or more when
levels of fibrinogen, prothrombin, and Factor X decreased to levels
of <10%, <10%, and 60% of normal, respectively. A
representative summary of the studies for Factor X is shown in FIG.
6. A decrease in antithrombin of 90% of normal led to a decrease in
clotting time of 25%. The ENOX test is dependent upon these
critical coagulation factors in the common cascade. B. Drug Effects
and Common Interferences In vitro experiments using citrated whole
blood indicates the ENOX test is insensitive to lipids (to 20
mg/ml), antiplatelet agents (abciximab, eptifibatide, tirofiban,
aspirin) and fibrinolytic agents (alteplase, tenecteplase), and
hematocrit. Hemodilution with IsoLyte or saline to 15% did not
affect test results, Table 5.
5TABLE 5 Summary of Interference Testing For Rapidpoint .RTM. ENOX
Test Sample Interferent Tested EFFECT Type Lipid No effect 0-20
mg/ml CWB Hematocrit No effect 20-50% HCT CWB Hemodilution No
effect at 15% CWB Tirofiban No effect at 0-5600 ng/ml CWB Aspirin
No effect at 0-300 ug/ml CWB Abciximab No effect at 0-3600 ng/ml
CWB Eptifibatide No effect at 0-2600 ng/ml CWB Ketorolac
tromethamine No effect at 0-12 ng/ml CWB Alteplase No effect at
1000-3200 ng/ml CWB Tenecteplase No effect at 0-10,000 ng/ml CWB
Nitroglycerin No effect at 0-1000 ng/ml CWB
[0079] Repeatability in preparation of assay and performance of
assay The within run CV values for 0.0 and 1.0 Iu/ml enoxaparin
samples were 6.3 and 5.5% and the lot-to-lot CV values for 0.0 and
1.0 IU/ml enoxaparin samples were 5.2 and 5.5%, respectively. Total
imprecision at 1.0 IU/ml enoxaparin was <7.0%.
[0080] It will be apparent from the above detailed description that
there are many variations in the present invention and the same are
deemed to be subject to this invention as set forth in the appended
claims.
* * * * *